Why the study?
Does sorafenib improve treatment response in a patient with highly recurrent, locally invasive DFSP refractory to imatinib and radiation?
Does sorafenib improve treatment response in a patient with highly recurrent, locally invasive DFSP refractory to imatinib and radiation?
Sorafenib may be an effective treatment option for highly recurrent, locally invasive DFSP that is refractory to imatinib and radiation therapy.
Hypothesis-generating for sorafenib in imatinib-refractory DFSP; prospective trials needed before clinical adoption.
DFSP is a locally invasive, slow-growing tumor of the subcutaneous tissue that rarely metastasizes but recurs frequently after surgical excision. We report herein a case of highly recurrent, locally invasive DFSP that failed both postoperative radiation therapy and complete trial of Imatinib, but was successfully treated with Sorafenib, which showed unprecedented response.
No takes yet. Share an insight, caveat, or question.
Kamar et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: